Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.
Also called NCT07434661
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 120 participants
- Registry
-
NCT07434661
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Russia
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07434661. Randomized; no masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2028-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR
- Acronym
- SAFE-HEART
- Condition
- Valve Disease, Heart
- Condition
- Atrial Fibrillation (AF)
- Condition
- Valve Replacement Surgery
- Condition
- Aortic Valve Surgery
- Condition
- Mitral Valve Annuloplasty
- Condition
- Mitral Valve Repair
- Condition
- Mitral Valve Surgery
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Warfarin
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
Record details
- Record id
cardio:ct-nct07434661- Content hash
5c49c6603fc687a9318ee99b32e6bfba330b0226c80fb9fbd2ff4903f32c047b